This phase 3 immunobridging study evaluated the Ad26/protein preF RSV vaccine in adults aged 18-59, with and without chronic cardiac or pulmonary conditions. Immune responses in both younger and high-risk adults were noninferior to those seen in adults aged 65 and older, in whom vaccine efficacy had been established. AMR Clinical sites contributed to enrollment. Safety and reactogenicity were clinically acceptable, though more frequent in younger adults.
Read this publication to explore:
- Immune response durability and age-based comparisons
- Reactogenicity and safety data by age and risk group
- Basis for inferring RSV vaccine efficacy in high-risk adults under 60